Latest Breaking News On - போர்த ஹவாஸ் சர்வதேச நிதி தகவல்தொடர்புகள் குழு - Page 6 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China . Apollomics, Inc.February 12, 2021 GMT FOSTER CITY, Calif. and HANGZHOU, ZHEJIANG, China, Feb. 12, 2021 (GLOBE NEWSWIRE) Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced an exclusive license agreement for the development and commercialization of TYG100 in Mainland China, Hong Kong, Macau and Taiwan, also known as Greater China, and South Africa. TYG100 is an antigen-specific, active checkpoint control immunotherapy (ACCI) recombinant vaccine comprising the amino-terminal sequence of G17, a gastrointestinal peptide hormone, and utilizes the S-TIR™ technology platform. This technology induces a novel mechanism of action that is able to unmask tumors. TYG100 was developed by T

Jian niHong kongUnited kingdomSouth africaRemy bernardaGuo liang yuFred jacobsKelly fungWilsonw cheungPorda havas international finance communications groupCancer research united kingdomCorporate communicationsApollomics incMainland chinaGreater chinaCancer research united